Frequency and epidemiology of extended-spectrum β-lactamase-producing Enterobacteriaceae isolates susceptible to third-generation cephalosporins or to aztreonam

被引：3

作者：

Bert, F. ^{[1
]}

Bialek-Davenet, S. ^{[1
]}

Leflon-Guibout, V. ^{[1
]}

Noussair, L. ^{[1
]}

Nicolas-Chanoine, M. -H. ^{[1
]}

机构：

[1] Hop Beaujon, AP HP, Microbiol Serv, F-92110 Clichy, France

来源：

MEDECINE ET MALADIES INFECTIEUSES | 2014年 / 44卷 / 02期

关键词：

Extended-spectrum beta-lactamase; Enterobacteriaceae; Third-generation cephalosporins; Aztreonam;

D O I：

10.1016/j.medmal.2013.12.004

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Objective. - We evaluated among 400 strains of extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBLE) the rate of strains categorized as intermediate or resistant to 3rd generation cephalosporins or aztreonam according to the 2011 guidelines of the French Society of Microbiology Antibiogram Committee. Material and methods. - MICs of cefotaxime, ceftazidime, cefepime or aztreonam were determined by the E-test method for isolates with susceptible zones to these antibiotics. Results. - Overall, 109/400 (27.3%) isolates were susceptible to at least one of these 4 agents. Notably, 21.8% of Escherichia coli isolates were susceptible to ceftazidime, and 21.1% of Klebsiella pneumoniae isolates were susceptible to cefepime. Discrepancies between categorization by disk diffusion and MIC determination were observed for aztreonam and cefepime. Conclusion. - These results indicate alternatives to carbapenems for treating infections caused by ESBLE. (C) 2014 Elsevier Masson SAS. All rights reserved.

引用

页码：76 / 78

页数：3

共 9 条

[1]

Comite de l'antibiogramme de la Societe francaise de microbiologie (CASFM), 2011, REC

[2] Phenotypic detection of extended-spectrum β-lactamase production in Enterobacteriaceae:: review and bench guide [J].

Drieux, L. ;

Brossier, F. ;

Sougakoff, W. ;

Jarlier, V. .

CLINICAL MICROBIOLOGY AND INFECTION, 2008, 14 :90-103

[3] Alternatives to carbapenems in ESBL-producing Escherichia coli infections [J].

Fournier, D. ;

Chirouze, C. ;

Leroy, J. ;

Cholley, P. ;

Talon, D. ;

Plesiat, P. ;

Bertrand, X. .

MEDECINE ET MALADIES INFECTIEUSES, 2013, 43 (02) :62-66

[4] In vitro activity of tigecycline against carbapenemase-producing Acinetobacter baumannii [J].

Hawser, Stephen P. ;

Hackel, Meredith ;

Person, Mary B. ;

Higgins, Paul G. ;

Seifert, Harald ;

Dowzicky, Michael .

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2010, 36 (03) :289-290

[5] EUCAST expert rules in antimicrobial susceptibility testing [J].

Leclercq, R. ;

Canton, R. ;

Brown, D. F. J. ;

Giske, C. G. ;

Heisig, P. ;

MacGowan, A. P. ;

Mouton, J. W. ;

Nordmann, P. ;

Rodloff, A. C. ;

Rossolini, G. M. ;

Soussy, C. -J. ;

Steinbakk, M. ;

Winstanley, T. G. ;

Kahlmeter, G. .

CLINICAL MICROBIOLOGY AND INFECTION, 2013, 19 (02) :141-160

[6] Cefepime Therapy for Monomicrobial Bacteremia Caused by Cefepime-Susceptible Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae: MIC Matters [J].

Lee, Nan-Yao ;

Lee, Ching-Chi ;

Huang, Wei-Han ;

Tsui, Ko-Chung ;

Hsueh, Po-Ren ;

Ko, Wen-Chien .

CLINICAL INFECTIOUS DISEASES, 2013, 56 (04) :488-495

[7] Impact of changes in CLSI and EUCAST breakpoints for susceptibility in bloodstream infections due to extended-spectrum β-lactamase-producing Escherichia coli [J].

Rodriguez-Bano, J. ;

Picon, E. ;

Navarro, M. D. ;

Lopez-Cerero, L. ;

Pascual, A. .

CLINICAL MICROBIOLOGY AND INFECTION, 2012, 18 (09) :894-900

[8] In vitro activity of beta-lactam antibiotics against CTX-M-producing Escherichia coli [J].

Tarnberg, M. ;

Ostholm-Balkhed, A. ;

Monstein, H. -J. ;

Hallgren, A. ;

Hanberger, H. ;

Nilsson, L. E. .

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2011, 30 (08) :981-987

[9]

The Comite de l'Antibiogramme of the Societe Franccaise de Microbiologie (CASFM), 2010, REC

← 1 →